Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.84
+0.40003.22%
Post-market: 13.020.1800+1.40%19:50 EDT
Volume:3.35M
Turnover:43.22M
Market Cap:1.80B
PE:-3.84
High:13.13
Open:12.65
Low:12.65
Close:12.44
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:0.92
T/O Rate:2.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.47
PE(LYR):-3.37

Loading ...

Intellia Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research

TIPRANKS
·
Jul 16

Movement Alert|Intellia Therapeutics Falls 9.74% in Regular Trading, Trading at $12.84

Market Focus
·
Jul 14

Intellia Therapeutics (NTLA) Is Down 12.1% After Positive Phase 3 Lonvo-z Data And 2027 Launch Plans - What's Changed

Simply Wall St.
·
Jul 11

Intellia Therapeutics (NTLA) Gets a Hold from Wedbush

TIPRANKS
·
Jul 10

Intellia Therapeutics is Maintained at Neutral by Wedbush

Dow Jones
·
Jul 10

Wedbush Raises Intellia Therapeutics Price Target to $17 From $12, Maintains Neutral Rating

MT Newswires Live
·
Jul 10

Intellia CFO Edward J. Dulac III Disposes of 4,677 Common Shares Valued at $84,186

Reuters
·
Jul 07

Intellia Grants 53,250 Inducement Rsus to 13 New Hires Under 2024 Plan

Reuters
·
Jul 07

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 07

Intellia Therapeutics rises 10.7%

TIPRANKS
·
Jun 17

Intellia Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jun 17

Small U.S. Stocks End Mixed As Intellia Therapeutics Leads, Bandwidth Cl A Lags

Dow Jones
·
Jun 16

Intellia Therapeutics Shares Climb Following Positive Phase 3 Results

Dow Jones
·
Jun 16

Wedbush Remains a Hold on Intellia Therapeutics (NTLA)

TIPRANKS
·
Jun 15

Intellia says Phase 3 HAELO trial shows 87% attack reduction with lonvo-z in hereditary angioedema

Reuters
·
Jun 15

Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO)

TIPRANKS
·
Jun 15

Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 15

Analysts’ Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR)

TIPRANKS
·
Jun 15

Intellia Therapeutics presents additional results from Phase 3 HAELO trial

TIPRANKS
·
Jun 15

Intellia reports Phase 3 trial shows lonvo-z cuts hereditary angioedema attacks 87% vs placebo

Reuters
·
Jun 13